What is the present valuation and projected CAGR of the pneumonia therapeutics market?
The pneumonia therapeutics market size has grown rapidly in recent years. It will grow from $10.35 billion in 2024 to $11.49 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to increase in prevalence of drug-resistant strains, rise in awareness of pneumonia prevention, growth in elderly and immunocompromised populations, expanded vaccination programs, and improved healthcare infrastructure.
The pneumonia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $17.26 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to increasing antibiotic-resistant strains, growing prevalence of pneumonia in aging populations, expansion of telemedicine for early diagnosis, rising healthcare expenditures in emerging markets, increasing funding for infectious disease research, and heightened awareness campaigns. Major trends in the forecast period include development of monoclonal antibodies, adoption of inhalable antibiotics, innovation in mRNA-based vaccines, AI-driven diagnostic tools, adoption of host-targeted therapies, novel immunomodulators, and advancements in rapid point-of-care diagnostic platforms.
Get Your Free Sample of The Global Pneumonia Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21258&type=smp
What key drivers have fueled the pneumonia therapeutics market’s development over the years?
The rising prevalence of pneumonia is expected to drive the growth of the pneumonia therapeutics market going forward. Pneumonia refers to a lung infection that inflames the air sacs, often causing symptoms such as cough, fever, and difficulty breathing. Increasing pneumonia cases can be attributed to factors such as aging populations, air pollution, smoking, weakened immune systems, antimicrobial resistance, and the spread of respiratory infections like COVID-19 or influenza. Pneumonia therapeutics help to combat the infection’s cause, such as bacteria, viruses, or fungi, using targeted medications while supporting recovery through oxygen therapy, anti-inflammatory drugs, and symptom management. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based government agency, globally, pneumonia affects about 120 million people annually, causing approximately 1.3 million deaths. Nearly 80% of pediatric pneumonia deaths occur in children under 2 in developing countries. Therefore, the increasing prevalence of pneumonia is driving the growth of the pneumonia therapeutics market.
What is the segmentation for the pneumonia therapeutics market?
The pneumonia therapeutics market covered in this report is segmented –
1) By Product: Drugs, Vaccine, Oxygen Therapy
2) By Infection: Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Ventilator-Associated Pneumonia (VAP)
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End Use: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Drugs: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids, Other Drugs
2) By Vaccine: Pneumococcal Vaccines, Haemophilus Influenzae Type B (Hib) Vaccines, Influenza Vaccines, Other Vaccines
3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC), Non-Invasive Ventilation (NIV), Mechanical Ventilation, Other Oxygen Therapies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/pneumonia-therapeutics-global-market-report
Who are the most influential companies in the pneumonia therapeutics market?
Major companies operating in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., Tergene Biotech Limited.
What are the top industry trends projected to impact the pneumonia therapeutics market?
Major companies operating in the pneumonia therapeutics market focus on developing innovative drug formulations and treatment methods such as antibiotic drugs to address antibiotic resistance and improve patient outcomes. An antibiotic drug refers to a type of medication specifically designed to treat bacterial infections. For instance, in June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, collaborated with Cipla Limited, an India-based pharmaceutical company, to introduce cefepime-enmetazobactam. This antibiotic combination is used to treat complex infections, including UTIs and pneumonia, particularly those resistant to other medications. It helps combat bacterial resistance, ensuring effective treatment while minimizing the need for stronger antibiotics.
What are the major regional insights for the pneumonia therapeutics market, and which region holds the top position?
North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumonia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Pneumonia Therapeutics Market Report 2025 Offer?
The pneumonia therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Pneumonia therapeutics refer to a range of treatments and medications used to manage and treat pneumonia, a lung infection that are caused by bacteria, viruses, or fungi. These therapeutics target the underlying pathogens, reduce inflammation, and improve respiratory functions. Treatments include antibiotics for bacterial pneumonia, antiviral medications for viral pneumonia, and antifungal agents for fungal infections.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21258
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
